Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and-2

被引:85
作者
Sadowski, Lauren A. [1 ]
Upadhyay, Rista [1 ,2 ]
Greeley, Zachary W. [1 ,4 ]
Margulies, Barry J. [1 ,3 ]
机构
[1] Towson Univ, Towson Univ Herpes Virus Lab, Dept Biol Sci, Towson, MD 21252 USA
[2] Towson Univ, Dept Chem, Towson, MD 21252 USA
[3] Towson Univ, Mol Biol Biochem & Bioinformat Program, Towson, MD 21252 USA
[4] Becton Dickinson, Sparks, MD 21152 USA
来源
VIRUSES-BASEL | 2021年 / 13卷 / 07期
关键词
acyclovir; ganciclovir; cidofovir; vidarabine; foscarnet; amenamevir; docosanol; nelfinavir; HSV-1; HSV-2; DNA-POLYMERASE; CYTOMEGALOVIRUS-INFECTION; CLINICAL PHARMACOKINETICS; PREEXPOSURE PROPHYLAXIS; ANTIVIRAL ACTIVITY; RESISTANCE; ACYCLOVIR; FOSCARNET; MECHANISM; TYPE-1;
D O I
10.3390/v13071228
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Herpes simplex viruses-1 and -2 (HSV-1 and -2) are two of the three human alphaherpesviruses that cause infections worldwide. Since both viruses can be acquired in the absence of visible signs and symptoms, yet still result in lifelong infection, it is imperative that we provide interventions to keep them at bay, especially in immunocompromised patients. While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses.
引用
收藏
页数:12
相关论文
共 86 条
[1]  
ADUMA P, 1995, MOL PHARMACOL, V47, P816
[2]  
Aebersold P M, 1979, Adv Ophthalmol, V38, P214
[3]   A comprehensive insight on ocular pharmacokinetics [J].
Agrahari, Vibhuti ;
Mandal, Abhirup ;
Agrahari, Vivek ;
Trinh, Hoang M. ;
Joseph, Mary ;
Ray, Animikh ;
Hadji, Hicheme ;
Mitra, Ranjana ;
Pal, Dhananjay ;
Mitra, Ashim K. .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2016, 6 (06) :735-754
[4]  
Ahmed Amina, 2011, Infect Disord Drug Targets, V11, P475
[5]   Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene [J].
Andrei, G ;
Snoeck, R ;
De Clercq, E ;
Esnouf, R ;
Fiten, P ;
Opdenakker, G .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :639-648
[6]   Characterization of herpes simplex virus type 1 thyraidine kinase mutants selected under a single round of high-dose brivudin [J].
Andrei, G ;
Balzarini, J ;
Fiten, P ;
De Clercq, E ;
Opdenakker, G ;
Snoeck, R .
JOURNAL OF VIROLOGY, 2005, 79 (09) :5863-5869
[7]   Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial [J].
Baeten, Jared M. ;
Donnell, Deborah ;
Mugo, Nelly R. ;
Ndase, Patrick ;
Thomas, Katherine K. ;
Campbell, James D. ;
Wangisi, Jonathan ;
Tappero, Jordan W. ;
Bukusi, Elizabeth A. ;
Cohen, Craig R. ;
Katabira, Elly ;
Ronald, Allan ;
Tumwesigye, Elioda ;
Were, Edwin ;
Fife, Kenneth H. ;
Kiarie, James ;
Farquhar, Carey ;
John-Stewart, Grace ;
Kidoguchi, Lara ;
Coombs, Robert W. ;
Hendrix, Craig ;
Marzinke, Mark A. ;
Frenkel, Lisa ;
Haberer, Jessica E. ;
Bangsberg, David ;
Celum, Connie .
LANCET INFECTIOUS DISEASES, 2014, 14 (11) :1055-1064
[8]   New antivirals - mechanism of action and resistance development [J].
Balzarini, J ;
Naesens, L ;
De Clercq, E .
CURRENT OPINION IN MICROBIOLOGY, 1998, 1 (05) :535-546
[9]   DNA polymerases as therapeutic targets [J].
Berdis, Anthony J. .
BIOCHEMISTRY, 2008, 47 (32) :8253-8260
[10]   HSV antivirals - current and future treatment options [J].
Birkmann, Alexander ;
Zimmermann, Holger .
CURRENT OPINION IN VIROLOGY, 2016, 18 :9-13